Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8788249 | 0.85 | HTT (0.61) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL896976 | 0.83 | SMN1; SMN2 (0.55) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL11092309 | 0.83 | SMN1; SMN2 (0.55) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL439092 | 0.80 | ADRA2A (0.60) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL20445516 | 0.80 | ADRA2A (0.56) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL9671960 | 0.80 | ADRA2A (0.56) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL7199309 | 0.80 | ADRA2A (0.56) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL3266284 | 0.80 | ADRA2A (0.60) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL11484814 | 0.80 | ADRA2A (0.56) | ADRA2AADRA1AHTR1AHTTDRD1 | |
| SCHEMBL8186813 | 0.80 | ADRA2A (0.60) | ADRA2AADRA1AHTR1AHTTDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105061392-B | A kind of guanoxan sulfate synthetic method | 上海现代哈森（商丘）药业有限公司 | 2017-07-18 | — | — | CN | claimed |
| CN-102503929-A | Synthesis method for guanoxan sulfate | SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD | 2012-06-20 | — | — | CN | claimed |
| CN-110981865-B | Medicine for treating brain glioma and preparation method thereof | 佳木斯大学 | 2021-01-12 | — | — | CN | disclosed |
| CN-110981865-A | Medicine for treating brain glioma and preparation method thereof | 佳木斯大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-105061392-B | A kind of guanoxan sulfate synthetic method | 上海现代哈森（商丘）药业有限公司 | 2017-07-18 | — | — | CN | disclosed |
| CN-105061392-A | Guanoxan sulfate synthesis method | SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD | 2015-11-18 | — | — | CN | disclosed |
| CN-102503929-A | Synthesis method for guanoxan sulfate | SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD | 2012-06-20 | — | — | CN | disclosed |
| CN-102503929-A | Synthesis method for guanoxan sulfate | SHANGHAI MODERN HASEN SHANGQIU PHARMACEUTICAL CO LTD | 2012-06-20 | — | — | CN | disclosed |
| US-7981912-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100016389-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-7601749-B2 | Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-4470989-A | Neuroleptic n-oxacyclyl-alkylpiperidine derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-09-11 | — | — | US | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4416895-A | ANTICOAGULANTS, ANTISHOCK AGENTS | BURROUGHS WELLCOME CO. (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0014295-B1 | BENZODIOXAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL APPLICATIONS | Bouchara, Emile Dr. (FR) | 1983-01-19 | — | — | EP | disclosed |
| EP-0068261-A1 | N-oxacyclyl-alkylpiperidine derivatives, their preparation, pharmaceutical preparations containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-05 | — | — | EP | disclosed |
| US-4309428-A | Maytansinoids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| EP-0025496-A1 | Maytansinoids, their production and therapeutic compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-03-25 | — | — | EP | disclosed |
| EP-0014295-A1 | Benzodioxan derivatives, process for their preparation and their therapeutical applications | Bouchara, Emile Dr. (FR) | 1980-08-20 | — | — | EP | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016389-A1 | INDOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | PTGDR2, TBXA2R, HCAR2 | ADRA2A 55/4885ADRA1A 256/4885HTR1A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.